| 程 聪,吴英英,林山锑,雷丽萍,刘有顺.富马酸替诺福韦二吡呋酯片联合双环醇在治疗慢性乙型病毒性肝炎方面的研究[J].现代生物医学进展英文版,2021,(3):502-505. |
| 富马酸替诺福韦二吡呋酯片联合双环醇在治疗慢性乙型病毒性肝炎方面的研究 |
| The Study of Tenofovir Dipivoxil Fumarate Tablets (TDF) Combined with Bicyclol in the Treatment of Chronic Hepatitis B |
| Received:July 03, 2020 Revised:July 27, 2020 |
| DOI：10.13241/j.cnki.pmb.2021.03.021 |
| 中文关键词: 富马酸替诺福韦二吡呋酯片 双环醇 慢性乙型病毒性肝炎 |
| 英文关键词: Tenofovir fumarate dipivoxil tablets Bicyclol Chronic hepatitis B |
| 基金项目:福建省自然科学基金项目(2018J0547) |
|
| Hits: 1037 |
| Download times: 770 |
| 中文摘要: |
| 摘要 目的：研究探讨富马酸替诺福韦二吡呋酯片（tenofovir dipivoxil fumarate tablets，TDF）联合双环醇在治疗慢性乙型病毒性肝炎方面的临床效果。方法：选取2017年1月-2020年1月中国人民解放军陆军第七十三集团军医院疾病预防控制科感染病区收治的80例慢性乙型病毒性肝炎患者，随机将其分为两组，对照组40例，给予TDF治疗，研究组40例，给予TDF联合双环醇治疗，观察两组治疗后的疗效及不良反应率，检测两组治疗前后血清乙型肝炎病毒DNA（Deoxyribonucleic acid）的水平及血清丙氨酸氨基转移酶（ALT）的水平。结果：治疗后，研究组总有效率95.0 %，显著高于对照组总有效率75.0 %(P＜0.05)；研究组血清乙型肝炎病毒DNA的水平<500 cps/mL的有32例，占80.0 %，对照组<500 cps/mL的有14例，占35.0 %，对比有统计学意义(P＜0.05)；两组血清ALT的水平明显降低，且研究组低于对照组(P＜0.05)。研究组不良反应总发生率2.5 %明显低于对照组25.0 % (P＜0.05)。结论：富马酸替诺福韦二吡呋酯片（TDF）联合双环醇治疗慢性乙型病毒性肝炎疗效显著，能使患者体内血清乙型肝炎病毒DNA的水平显著的降低，且安全可靠，值得临床推广和应用。 |
| 英文摘要: |
| ABSTRACT Objective: To study the clinical effect of tenofovir dipivoxil fumarate tablets (TDF) combined with bicyclol in the treatment of chronic hepatitis B. Methods: From January 2017 to January 2020, 80 patients with chronic hepatitis B were randomly divided into two groups, 40 in the control group, treated with tenofovir dipivoxil fumarate tablets (TDF), 40 in the study group, treated with TDF combined with bicyclol, observed the curative effect and adverse reaction rate of the two groups, and tested the blood of the two groups before and after treatment. The level of hepatitis B virus DNA and serum ALT. Results: After treatment, the total effective rate of the study group was 95.0 %, which was significantly higher than the total effective rate of the control group of 75.0 % (P＜0.05). 32 cases of the study group had serum hepatitis B virus DNA levels <500 cps/mL, accounting for 80.0 %, there were 14 cases in the control group <500 cps/mL, accounting for 35.0 %, which was statistically significant (P<0.05). The serum ALT levels of the two groups were significantly reduced, and the study group was lower than the control group (P<0.05). The total incidence of adverse reactions in the study group was 2.5 % significantly lower than that in the control group 25.0 % (P＜0.05). Conclusion: TDF combined with bicyclol was effective in the treatment of chronic hepatitis B, which could greatly reduce the level of serum hepatitis B virus DNA（Deoxyribonucleic acid） in patients. It was safe and reliable, and worthy of clinical application. |
|
View Full Text
View/Add Comment Download reader |
| Close |
